Skip to content
Sign in

KPTI · NASDAQ

Karyopharm Therapeutics (KPTI) Stock Price & Fundamentals

$827.46−1.18%−$9.89End-of-day price as of Oct 9, 2026

Karyopharm Therapeutics (KPTI) closed at $827.46 on Oct 9, 2026, down 1.18% from the previous close of $837.35.

Share price, past year

1Y +14.96%

52-week range $689.07 – $842.44. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$827.46
Sep 30, 2026$818.57
Aug 31, 2026$812.66
Jul 31, 2026$792.65
Jun 30, 2026$788.46
May 29, 2026$774.07
Apr 30, 2026$759.35
Mar 31, 2026$730.77
Feb 27, 2026$730.53
Jan 30, 2026$714.06
Dec 31, 2025$737.88
Nov 28, 2025$704.69
Oct 31, 2025$700.47

Key statistics

Market cap
$18.77B
P/E (TTM)
—
EPS (TTM)
−$14.40
Revenue (TTM)
$146.62M
Net income (TTM)
−$224.74M
Shares outstanding
22.7M
Dividend yield
—
52-week range
$689.07 – $842.44

Karyopharm Therapeutics's market cap is $18.77B, based on a share price of $827.46 and 22.7M shares outstanding as of Jun 30, 2026.

Financials

Karyopharm Therapeutics reported revenue of $146.07M for fiscal 2025, up 0.57% from fiscal 2024.

Karyopharm Therapeutics reported a net loss of $196.04M in fiscal 2025.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Karyopharm Therapeutics annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$146.07M+0.6%−$196.04M−134.2%−$17.93−$75.37M
FY2024ended Dec 31, 2024$145.24M−0.6%−$76.42M−52.6%−$14.00−$127.63M
FY2023ended Dec 31, 2023$146.03M−7.0%−$143.10M−98.0%−$18.79−$92.72M
FY2022ended Dec 31, 2022$157.07M−25.1%−$165.29M−105.2%−$2.02−$149.67M
FY2021ended Dec 31, 2021$209.82M+94.1%−$124.09M−59.1%−$1.65−$107.33M
FY2020ended Dec 31, 2020$108.09M+164.3%−$196.27M−181.6%−$2.72−$160.38M
FY2019ended Dec 31, 2019$40.89M+34.8%−$199.59M−488.1%−$3.22−$191.03M
FY2018ended Dec 31, 2018$30.34M+1,790.1%−$178.41M−588.1%−$3.14−$161.48M
FY2017ended Dec 31, 2017$1.61M+942.2%−$128.98M−8,036.4%−$2.81−$73.78M
FY2016ended Dec 31, 2016$154.00K—−$109.58M−71,153.9%−$2.92−$84.46M
Karyopharm Therapeutics quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$33.43M−$67.02M−$2.32
Q1 FY2026ended Mar 31, 2026$35.07M−$22.39M−$1.24
Q4 FY2025ended Dec 31, 2025$34.08M−$102.20M−$7.02
Q3 FY2025ended Sep 30, 2025$44.04M−$33.13M−$3.82
Q2 FY2025ended Jun 30, 2025$37.93M−$37.25M−$4.32
Q1 FY2025ended Mar 31, 2025$30.02M−$23.46M−$2.77
Q4 FY2024ended Dec 31, 2024$30.54M−$30.78M−$2.33
Q3 FY2024ended Sep 30, 2024$38.78M−$32.07M−$3.85

Company profile

Name
Karyopharm Therapeutics Inc.
Ticker
KPTI
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
85 Wells Avenue, Second Floor, Newton, MA 02459
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001503802

Recent SEC filings

Frequently asked questions

What is Karyopharm Therapeutics's stock price?

Karyopharm Therapeutics (KPTI) closed at $827.46 on Oct 9, 2026, down 1.18% from the previous close of $837.35.

What is Karyopharm Therapeutics's market cap?

Karyopharm Therapeutics's market cap is $18.77B, based on a share price of $827.46 and 22.7M shares outstanding as of Jun 30, 2026.

How much revenue does Karyopharm Therapeutics make?

Karyopharm Therapeutics reported revenue of $146.07M for fiscal 2025, up 0.57% from fiscal 2024.

Does Karyopharm Therapeutics pay a dividend?

Karyopharm Therapeutics's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Karyopharm Therapeutics Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures